Aeglea BioTherapeutics' IPO

Aeglea BioTherapeutics raised a round of funding on April 07, 2016. Investors include Public.

Aeglea was founded in 2013 to develop engineered human enzymes. Aeglea's pipeline of engineered human enzymes includes AEB1102, which is expected to enter into clinical trials in both hyperargininemia…

Articles about Aeglea BioTherapeutics' IPO: